Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats

@article{Zuideveld2002PharmacokineticPharmacodynamicMO,
  title={Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats},
  author={Klaas P. Zuideveld and Jasna Rusi{\'c}-Pavleti{\'c} and Hugo J. Maas and Lambertus A. Peletier and Piet H. van der Graaf and Meindert Danhof},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2002},
  volume={303},
  pages={1130 - 1137}
}
The objective of this investigation was to compare the in vivo potency and intrinsic activity of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats by pharmacokinetic-pharmacodynamic modeling. Following intravenous administration of buspirone (5 or 15 mg/kg in 15 min) or 1-PP (10 mg/kg in 15 min), the time course of the concentrations in blood were determined in conjunction with the effect on body temperature. The pharmacokinetics of buspirone and 1-PP were analyzed based… 

Figures and Tables from this paper

6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats

Preclinical data suggest that 6-OH-buspirone probably contributes to the clinical efficacy of buspirone as an anxiolytic agent.

Pharmacokinetic–Pharmacodynamic Modeling of the Hydroxy Lerisetron Metabolite L6-OH in Rats: An Integrated Parent–Metabolite Model

It is concluded that after lerisetron administration, L6-OH is extensively formed in the rat but it is quickly eliminated; therefore, besides being equipotent with the parent drug, the L 6-OH metabolite does not influence the effect of ler isetron.

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

A full mechanistic PK-PD model for 5-HT1A receptor agonists has been obtained, which is highly predictive of the in vivo intrinsic efficacy and a highly significant correlation was observed between the efficacy parameters in vivo and in vitro.

Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response

Based on competitive PK/PD analysis of the parent–metabolite interaction, the relative contribution of dehydrosertindole to the overall pharmacological effect after sertindoles administration in rats appeared to be of minor significance.

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.

AIMS To describe the population pharmacokinetic-pharmacodynamic relationship between darifenacin (UK-88,525) and its hydroxylated metabolite (UK-148,993), and the reduction in salivary flow (SF, a

Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics

The findings of this study show that the rate-limiting step in the onset and offset of buprenorphine's antinociceptive effect is distribution to the brain.

CYP2D6 CATALYZES 5-HYDROXYLATION OF 1-(2-PYRIMIDINYL)-PIPERAZINE, AN ACTIVE METABOLITE OF SEVERAL PSYCHOACTIVE DRUGS, IN HUMAN LIVER MICROSOMES

Results indicate that polymorphic CYP2D6 is responsible for the conversion of 1-PP to HO-1-PP, the major metabolite in the human circulation and in rat brains following oral administration of buspirone.

CYP 2 D 6 CATALYZES 5-HYDROXYLATION OF 1-( 2-PYRIMIDINYL )-PIPERAZINE , AN ACTIVE METABOLITE OF SEVERAL PSYCHOACTIVE DRUGS , IN HUMAN LIVER MICROSOMES

Results indicate that polymorphic CYP2D6 is responsible for the conversion of 1-PP to HO-1-PP, a major urinary metabolite resulting from the N-dealkylation of several antidepressant/anxiolytic 5-HT1A agonists including buspirone.

Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic‐pharmacodynamic modelling approach

A thorough characterization of the pharmacokinetic (PK) properties of tesofensine and M1 in mice is accomplished and the potency and concentration‐time course of the active metabolite M1 relative to tes ofensine are evaluated using the PK/PD modelling approach.

References

SHOWING 1-10 OF 55 REFERENCES

1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat.

Results, together with the fact that PmP is biochemically and pharmacologically active, suggest that the metabolite may contribute significantly to the central effects of the parent drug.

Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat.

Results indicate that PmP formation is a pharmacologically significant process for both buspirone and MJ-13805 but it is probably less important for piribedil.

Metabolism of the antianxiety drug buspirone in human subjects.

The metabolism of an oral dose of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects to facilitate structural characterization of the metabolites by mass spectrometry.

Metabolism of the antianxiety drug buspirone in the rat.

Seven major metabolites of the antianxiety drug buspirone were unambiguously identified together with unchanged drug and accounted for greater than 90% of the total metabolites excreted in the rat bile and urine samples.

Analysis of the hypothermic action of 8-hydroxy-2-(di-N-propylamino)-tetralin, and of 1-(2-pyrimidinyl)-piperazine and its derivatives

It was concluded that hypothermic effects of 8-OH-DRAT, buspirone and its structure analogues were bound with preferable influence as partial agonists on the postsynaptic serotonine 1A receptors.

A competitive interaction model predicts the effect of WAY-100,635 on the time course of R-(+)-8-hydroxy-2-(di-n-propylamino)tetralin-induced hypothermia.

The findings of this investigation show that, in contrast to earlier reports in the literature, WAY 100,635 behaves as a pure competitive antagonist at the 5-hydroxytryptamine(1A) receptor in vivo.
...